Minjuvi 200 mg, poudre pour solution à diluer pour perfusion - + + Swissmedic Key 68083001 Registration Holder Incyte Biosciences International Sàrl Name Minjuvi 200 mg, poudre pour solution à diluer pour perfusion Date of registration 22.03.2022 Introduction of Sequence 22.03.2022 ATC-Classification (L01FX12) Revision date WHO WHO-DDD Valid until 20.05.2030 Index Therapeuticus (BSV) 07.16.10. Show package size + + Index Therapeuticus (Swissmedic) 07.16.10. Description Swissmedic categorie. A SL Eintrag Yes Indication Information for professionals IP Consumer information Ex-factory-Price 678.34 Limitation Yes Limitation text
Deductible 10 % Consumer price 754.15 Feedback FB GTIN 7680680830017 Medication Code Biotechnologika Pharmacode Disponibility
Composition Praeparatio cryodesiccata: tafasitamabum 200 mg, natrii citras dihydricus corresp. natrium 7.4 mg, acidum citricum monohydricum, trehalosum dihydricum, polysorbatum 20, pro vitro. Packungsbestandteile Label Praeparatio cryodesiccata:
Galenic Form poudre pour solution à diluer pour perfusion Excipiens Active Agent Dose Tafasitamabum 200 mg
BAG: Active Agent Dose Tafasitamabum 200 mg
Inactive agents Citric Acid Monohydrate Natrii Citras Dihydricus Polysorbatum 20 Trehalosum Dihydricum
Source Data was imported : 06.06.2025
Swissmedic Registration :
Sequence :
Product name :
Registration owner: :
Product group :
Index Therapeuticus (BSV) :
Medication Code :
Date of registration :
Valid until :
Package number :
Show package size :
Commercial Form/Unit :
Swissmedic categorie. :
Active Agents :
Composition :
